全文获取类型
收费全文 | 222572篇 |
免费 | 50805篇 |
国内免费 | 4781篇 |
专业分类
耳鼻咽喉 | 2476篇 |
儿科学 | 7169篇 |
妇产科学 | 1636篇 |
基础医学 | 33986篇 |
口腔科学 | 9504篇 |
临床医学 | 23213篇 |
内科学 | 40845篇 |
皮肤病学 | 7131篇 |
神经病学 | 26357篇 |
特种医学 | 8902篇 |
外国民族医学 | 7篇 |
外科学 | 21619篇 |
综合类 | 16979篇 |
现状与发展 | 13篇 |
一般理论 | 12篇 |
预防医学 | 18623篇 |
眼科学 | 3026篇 |
药学 | 30636篇 |
43篇 | |
中国医学 | 10626篇 |
肿瘤学 | 15355篇 |
出版年
2024年 | 316篇 |
2023年 | 1853篇 |
2022年 | 3248篇 |
2021年 | 5902篇 |
2020年 | 9959篇 |
2019年 | 14401篇 |
2018年 | 13892篇 |
2017年 | 15374篇 |
2016年 | 14855篇 |
2015年 | 14718篇 |
2014年 | 17725篇 |
2013年 | 18923篇 |
2012年 | 16863篇 |
2011年 | 17308篇 |
2010年 | 14464篇 |
2009年 | 10684篇 |
2008年 | 11359篇 |
2007年 | 9833篇 |
2006年 | 8966篇 |
2005年 | 8271篇 |
2004年 | 7499篇 |
2003年 | 6715篇 |
2002年 | 5950篇 |
2001年 | 4941篇 |
2000年 | 3417篇 |
1999年 | 2004篇 |
1998年 | 1680篇 |
1997年 | 1495篇 |
1996年 | 1333篇 |
1995年 | 1321篇 |
1994年 | 1155篇 |
1993年 | 923篇 |
1992年 | 941篇 |
1991年 | 869篇 |
1990年 | 813篇 |
1989年 | 783篇 |
1988年 | 716篇 |
1987年 | 649篇 |
1986年 | 643篇 |
1985年 | 885篇 |
1984年 | 805篇 |
1983年 | 585篇 |
1982年 | 587篇 |
1981年 | 533篇 |
1980年 | 496篇 |
1979年 | 353篇 |
1978年 | 262篇 |
1977年 | 218篇 |
1976年 | 191篇 |
1975年 | 135篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的:探讨消化道肿瘤中同源重组修复相关基因(homologous recombination repair related gene,HRR)突变的发生情况及临床意义。方法:共92例消化道肿瘤患者,79例患者进行了血液标本HRR检测,53例患者进行了组织标本HRR检测,40例患者同时行血液和组织的HRR基因检测,收集患者基因检测结果及临床相关资料。结果:在79例患者血液标本检测中发现10例(12.6%)有临床意义HRR突变,在53例患者组织标本检测中发现9例(17.0%)有临床意义HRR突变。40例同时行血液和组织的HRR基因检测患者中常见的有临床意义HRR突变为CDK12突变4例(10.0%)、ATM突变3例(7.5%)、BRCA1突变2例(5.0%)。13例有临床意义HRR突变患者中常见共存突变为TP53突变10例(76.9%)、APC突变5例(38.5%)、PIK3CA突变4例(30.8%)。40例患者中13例患者血液和/或组织中有临床意义HRR突变,27例患者血液和组织中均无任何临床意义HRR突变且两组相比,有临床意义HRR突变组肿瘤突变负荷(tumor mutational burden,TMB)为6.17(2.24~11.52),而未携带HRR突变组TMB为0.4(0~3.75),差异有统计学意义(P<0.05)。40例患者组织检测中7例HRR有临床意义的突变,33例无HRR突变,血液检测中10例HRR有临床意义的突变,30例无HRR突变,一致性检验的Kappa值为0.333(P=0.031)。结论:携带有临床意义HRR突变的消化道肿瘤患者TMB更高,血液和组织检测HRR突变有较好的一致性。 相似文献
2.
3.
4.
5.
6.
《Cancer cell》2021,39(9):1214-1226.e10
- Download : Download high-res image (204KB)
- Download : Download full-size image
7.
8.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
9.
Weina Cheng Yazhi Wang Jingxian Liu Xiaofei Li Ming Yu Cancan Duan Liu Liu Jianyong Zhang 《Journal of applied toxicology : JAT》2022,42(6):970-980
Cantharidin (CTD) is an effective antitumor agent. However, it exhibits significant hepatotoxicity, the mechanism of which remains unclear. In this study, biochemical and histopathological analyses complemented with ultra-high-performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS)-based targeted metabolomic analysis of bile acids (BAs) were employed to investigate CTD-induced hepatotoxicity in rats. Sixteen male and female Sprague–Dawley rats were randomly divided into two groups: control and CTD (1.0 mg/kg) groups. Serum and liver samples were collected after 28 days of intervention. Biochemical, histopathological, and BA metabolomic analyses were performed for all samples. Further, the key biomarkers of CTD-induced hepatotoxicity were identified via multivariate and metabolic pathway analyses. In addition, metabolite–gene–enzyme network and Kyoto Encyclopedia of Genes and Genomes pathway analyses were used to identify the signaling pathways related to CTD-induced hepatotoxicity. The results revealed significantly increased levels of biochemical indices (alanine aminotransferase, aspartate aminotransferase, and total bile acid). Histopathological analysis revealed that the hepatocytes were damaged. Further, 20 endogenous BAs were quantitated via UHPLC-MS/MS, and multivariate and metabolic pathway analyses of BAs revealed that hyocholic acid, cholic acid, and chenodeoxycholic acid were the key biomarkers of CTD-induced hepatotoxicity. Meanwhile, primary and secondary BA biosynthesis and taurine and hypotaurine metabolism were found to be associated with the mechanism by which CTD induced hepatotoxicity in rats. This study provides useful insights for research on the mechanism of CTD-induced hepatotoxicity. 相似文献
10.
《Bulletin du cancer》2023,110(2):145-150